Clofarabine: a new treatment option for patients with acute myeloid leukemia.

Abstract

Clofarabine is a rationally designed, second-generation deoxyadenosine analog that incorporates characteristics of two other purine analogs, fludarabine and cladribine. It has shown efficacy in hematologic malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia and myelodysplastic syndrome. It has already been approved for use in pediatric acute lymphoblastic leukemia after two lines of previous therapy. Clinical trials have also shown clofarabine to have activity both as a single agent and in combination with other cytotoxic drugs in adult myeloid leukemia. This compound seems to have efficacy in older patients, as well as those with adverse cytogenetics.

• Authors: Melissa L Larson, Parameswaran Venugopal
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 10 Issue 8 Pg. 1353-7 (Jun 2009) ISSN: 1744-7666 [Electronic] England
• PMID: 19463072 (Publication Type: Journal Article, Review)

Chemical References

• Adenine Nucleotides
• Antineoplastic Agents
• Arabinonucleosides
• Clofarabine

Topics

• Adenine Nucleotides (adverse effects, pharmacokinetics, therapeutic use)
• Adult
• Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
• Arabinonucleosides (adverse effects, pharmacokinetics, therapeutic use)
• Clofarabine
• Humans
• Leukemia, Myeloid, Acute (drug therapy)